Cargando...
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
PURPOSE: Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibi...
Guardado en:
| Publicado en: | J Clin Oncol |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society of Clinical Oncology
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6816000/ https://ncbi.nlm.nih.gov/pubmed/27138582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.8931 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|